简化分子国际预后指数作为临床试验入组标准:土耳其淋巴瘤研究组大B细胞淋巴瘤队列分析
该多中心队列纳入2012至2024年诊断的1439例大B细胞淋巴瘤患者,评估简化分子国际预后指数(smIPI)作为试验入组标准的潜力。smIPI将38.2%和5.3%的患者分别重分类至更高和更低风险组,重分类至高危组者进展风险增加(HR=1.34,p=0.003)。IPI与smIPI定义的高危组3年PFS相似(54.9% vs 56.3%),但smIPI使高危组人数扩大35.2%。
要点
- smIPI将38.2%患者重分类至更高风险组,5.3%重分类至更低风险组。
- smIPI重分类至高危组患者进展风险增加(HR=1.34,p=0.003)。
- IPI与smIPI高危组3年PFS相似(54.9% vs 56.3%),smIPI高危组扩大35.2%。
核心结论
- smIPI易于应用,在识别进展高风险、适合参与临床研究的患者方面比IPI更敏感。
研究设计与样本
- 多中心大B细胞淋巴瘤队列研究,纳入2012至2024年诊断的1439例患者,数据来自机构档案。
- 主要终点为无进展生存(PFS)的风险分层,采用Kaplan-Meier和Cox回归进行生存分析。
主要发现
- smIPI将38.2%的患者重分类至更高风险组,5.3%重分类至更低风险组(相较于IPI)。
- smIPI重分类至更高风险组的患者进展风险高于其余组(HR=1.34,p=0.003)。
- IPI与smIPI定义的高危组3年PFS相似(54.9% vs 56.3%),但smIPI定义的高危组人数扩大35.2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Comparative first-line trials in large B-cell lymphoma (LBCL) have mostly failed over the last decade. Failures were commonly attributed to overestimation of the progression risk for the control arms, bringing the precision of the international prognostic index (IPI) into scrutiny. Simplified molecular IPI (smIPI), introduced at American Society of Hematology 2023, was developed to address the shortcomings of IPI. This study investigated smIPI and its potential implications as trial eligibility criteria among a multicentre LBCL cohort of 1439 patients. Patients diagnosed between 2012 and 2024 were included. Data were collected from institutional archives. The primary end-point was risk stratification for progression-free survival (PFS). Kaplan-Meier and Cox regression methods were used for survival analyses. The smIPI reclassified 38.2% and 5.3% of patients to higher and lower risk groups from IPI, respectively. Patients reclassified to higher risk groups by smIPI had an increased risk of progression than the rest of the group (hazard ratio = 1.34, p = 0.003). High-risk groups classified by IPI and smIPI had similar outcomes (3-year PFS 54.9% vs. 56.3%); however, the high-risk group size was expanded by 35.2% when defined by smIPI. The smIPI is easily applicable and more sensitive than IPI in identifying patients under high risk of progression who are ideal candidates to participate in clinical research.
引用
- Yılmaz U, Terzi Demirsoy E, Keklik Karadağ F, et al. Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort. Br J Haematol. 2025. PMID: 40524448. doi:10.1111/bjh.20111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。